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Diethanolamine (DEA) has been found to produce liver and kidney tumors in mice following lifetime
dermal exposures. Data regarding the mode of action by which DEA produces these tumors were used to
support a dose-response assessment that resulted in a no-signiﬁcant-risk-level (NSRL) for dermal ex-
posures to DEA. DEA and its metabolites are structural analogs to endogenous agents important to
choline homeostasis. Sufﬁcient information is available to support an epigenetic MOA involving the
perturbation of choline homeostasis and hepatic methylation reactions in the formation of mouse liver
tumors. This MOA may also apply to mouse kidney tumors, but direct measurements for key events in
kidney are lacking. For both tumor types, dose-response data were pooled across four cancer bioassays
conducted for DEA and DEA-containing condensates in order to provide a more robust characterization
of the dose-response relationships. Doses were expressed in terms of dermally absorbed dose so that the
dose-dependency and species differences in the dermal absorption of DEA were addressed. The resulting
NSRL value of 3400 ug/day for dermal exposures to DEA is considered to be protective of human health
for both tumor endpoints.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Diethanolamine (DEA, CASRN: 111-42-2) is a small, water-
soluble molecule that is used as a surfactant, corrosion inhibitor,
and in oil reﬁneries to remove hydrogen sulﬁde from natural gas. It
is also used in the production of diethanolamides that serve as
ingredients in cosmetics and shampoos. For these reasons, human
populations may be exposed to DEA via occupational exposure in
speciﬁc industries, and via use of DEA-fatty acid condensates in
consumer products (e.g., cosmetics, shampoos) (CIR, 2011). Fatty
acid condensates of DEA are produced by reacting fatty acids such
as oleic acid, lauric acid, and coconut oil fatty acids with dieth-
anolamine. These condensates differ widely with respect to the
amount for free DEA present in the mixture: oleic acid condensate
(0.19% DEA), lauric acid condensate (0.83% DEA), and coconut oil
acid condensate (18.2% DEA) (NTP, 1999abc). Lifetime dermal ex-
posures to DEA and DEA condensates dissolved in ethanol haveC.R. Kirman).
r Inc. This is an open access articlebeen shown to produce liver tumors in male and female mice, and
kidney tumors in male mice (NTP, 1999abc, 2001). NTP conducted a
logistic regression analysis of the pooled liver tumor results from all
four cancer bioassays for DEA and DEA condensates, and concluded
that tumor response was primarily determined by free DEA (NTP,
2001). However, with respect to the carcinogenicity of DEA, clear
species differences are apparent since no tumors were observed in
similarly exposed rats (NTP, 1999abc, 2001).
The mouse liver and kidney tumor data have been used to
support cancer dose-response assessments in the past. USEPA
(USEPA, 2001, 2002) assumed a mutagenic mode of action and used
a no threshold linear dose response model to derive dermal cancer
slope factor (CSF) values from the mouse tumor data ranging from
0.0075 to 0.4 (mg/kg-day)1. More recently, Wang et al. (2014) used
themouse tumor data and a linear, no threshold model, to calculate
a No-Signiﬁcant-Risk-Level (NSRL) of 1.4 ug/day for DEA. These
assessments for DEA are complicated by a number of factors,
including: (1) a very high background rate for liver tumors in mice
(i.e., greater than 60%); (2) the cancer bioassay for DEA (NTP, 1999a)
utilized doses that are too high to provide a useful characterization
of the dose-response relationship for DEA (i.e., nearly 100% tumorunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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on a maximum tolerated dose-based study design; (3) the dermal
absorption of DEA is dose-dependent (i.e., a greater fraction of
dermally applied dose is absorbed at higher doses); and (4) the
dermal absorption of DEA exhibits clear species differences
(Matthews et al., 1997; Sun et al., 1996) due to toxicokinetic factors
that are not addressed by allometric scaling of dose (e.g., body
weight raised to the ¾ power).
IARC (2013) recently reviewed the information for DEA and
concluded that there is inadequate evidence in humans for the
carcinogenicity of DEA, and that there is sufﬁcient evidence in
experimental animals for the carcinogenicity of DEA. IARC
concluded that therewasweak evidence of genotoxicity noting that
DEA was not genotoxic in most in vitro test systems, and did not
induce micronuclei in the mice test by NTP. Lastly, IARC concluded
that there was moderate experimental support for choline deﬁ-
ciency as the mechanism of carcinogenesis, but noted several lim-
itations in the database of mechanistic studies (see discussion in
Section 4 below).
Although California regulations (OEHHA, 2012; Title 27, Cali-
fornia Code of Regulations Article 7. No Signiﬁcant Risk Levels x
2570) describes speciﬁc methods for calculating NSRL values, these
regulations are also sufﬁciently ﬂexible to permit the use of the best
available science, e.g. “Nothing in this article shall preclude a person
from using evidence, standards, risk assessment methodologies, prin-
ciples, assumptions or levels not described in this article to establish
that a level of exposure to a listed chemical poses no signiﬁcant risk.”
(ibid). The goal of this work is to conduct a dose-response assess-
ment for DEA-induced tumor inmice based upon a consideration of
themode of action (MOA) using the best available science, data, and
methods.2. Methods
The published literature was searched (via Pubmed, Toxnet,
reference list for recent reviews), and reviewed to identify key data
sets for characterizing: (1) the MOA for DEA-induced mouse tu-
mors; (2) the dose-response relationship for tumors in mice
exposed to DEAvia dermal application; and (3) the toxicokinetics of
DEA in mice and humans. This information was summarized and
used to support decisions made in the dose-response assessment.
Cancer potency values were derived for DEA using the best
available science, in a manner that is consistent with available
USEPA guidelines (USEPA, 2005, 2012), using the following
equations:
Nonlinear Approach:
RfD ¼ POD/UFt (1)
NSRL ¼ RfD*BW*CF (2)
Where, RfD ¼ Reference dose (mg/kg-day); POD ¼ Point of depar-
ture (mg/kg-day, absorbed dose); UFt ¼ Total uncertainty factor
(unitless), which is calculated as the product of individual uncer-
tainty factors for interspecies variation (UFa), intraspecies variation
(UFh), LOAEL-to-NOAEL (UFl), subchronic-to-chronic extrapolation
(UFs), and database deﬁciencies (UFd); NSRL ¼ No-signiﬁcant-risk-
level (ug/day); BW ¼ Body Weight (70 kg); and CF ¼ Conversion
factor (1000 ug/mg)
Linear Approach:
CSF ¼ BMR/POD (3)
NSRL ¼ TR*BW*CF/CSF (4)Where, CSF ¼ Cancer slope factor (mg/kg-day)1;
BMR ¼ Benchmark response rate (0.1, unitless); POD ¼ Point of
departure (mg/kg-day); NSRL ¼ No-signiﬁcant-risk-level (ug/day);
TR ¼ Target risk (1  105); BW ¼ Body Weight (70 kg); and
CF ¼ Conversion factor (1000 ug/mg).
This assessment relies upon the calculation of absorbed dose of
DEA, which was calculated as follows:
MADD ¼ MADC*FDEA*ABSm (5)
Where,
MADD ¼ Mouse absorbed DEA dose (mg/kg-day);
MADC ¼ Mouse applied dose of DEA condensates as stated by
NTP (NTP, 1999abc, 2001);
FDEA ¼ Fraction DEA present in DEA condensates; and
ABSm ¼Mouse dermal absorption fraction (unitless); this value
is dose-dependent, and was estimated using the relationship
depicted in Fig. 3.
Subsequently, human equivalent doses were calculated and
expressed in terms of applied dose using the following equation:
HADD ¼ MADD/ABSH (6)
Where,
HADD ¼ Human Applied DEA Dose (mg/kg-day)
MADD ¼ Mouse Absorbed DEA Dose (mg/kg-day); and
ABSH ¼ Human dermal absorption fraction (unitless).
The dose-response assessment conducted for DEA includes the
following steps: (1) Endpoint/data set selection, which includes
consideration of data sets pooled together across several cancer
bioassays; (2) Dose measure calculation, which includes the esti-
mation of the dermal absorbed dose of DEA; (3) Dose-response
model selection of the observed data based upon a consideration
of model ﬁt; (4) Point-of-departure (POD) selection, which includes
calculations for determining the human equivalent dose (HED); (5)
Low-dose extrapolation, which included linear and nonlinear
methods; and (6) NSRL calculation. Several of these steps require a
consideration of the toxicokinetics and MOA for the carcinogenic
effects of DEA. For this reason, toxicokinetic and mechanistic data
from the published literature were reviewed prior to conducting
the dose-response assessment.
All dose-response modeling was performed using USEPA's
Benchmark Dose Software (BMDS, version 2.6). A number of
dichotomous models are available in this software, including
gamma, logistic, log-logistic, log-Probit, multistage, Probit, Weibull,
quantal-linear, and dichotomous Hill model. The best ﬁtting model
was selected based upon visual inspection, Akaike's information
criterion (AIC), and chi-square goodness-of-ﬁt p-value. The two
highest dose groups (46.2 and 147 mg/kg-day, absorbed dose) in
the pooled liver tumor data were dropped since a near-maximal
response (97%) was observed at 16.3 mg/kg-day and dropping
these two dose groups resulted in an improvement in the AIC and
p-values. A benchmark response rate (BMR) of 10% was considered
appropriate for the pooled data sets, consisted with USEPA guide-
lines (USEPA, 2012).
3. Results
3.1. Mode of action for Mouse liver and kidney tumors
MOA is deﬁned here as a sequence of key events, including
Fig. 1. DEA Metabolism (based on Matthews et al., 1995).
Fig. 2. Cholline transport and metabolism.
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the toxicodynamic processes that occur once DEA reaches thetarget tissue. This differs from previously used deﬁnitions for MOA,
where it was deﬁned to start with the chemical reaching the target
Fig. 3. Dose-Dependent Dermal Absorption of DEA in Mice and Rats in 48 h (Matthews et al., 1997).
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point) (USEPA, 2005). There is no risk without exposure, and
therefore, as Borgert et al. (2015) point out, best practices in
problem formulation for evaluating potential carcinogenic hazards
and risks, require due consideration of dosimetry when formu-
lating hypotheses. Although a complete evaluation of the cancer
MOA for DEA within existing frameworks (USEPA, 2005; Boobis
et al., 2008; Meek et al., 2014; Simon et al., 2014) is beyond the
scope of this paper, data regarding DEA toxicokinetics, choline
function and its perturbation by DEA and ethanol, and other po-
tential MOAs are discussed brieﬂy below to help guide decisions
made in the dose-response assessment (Section 3.2).3.1.1. DEA toxicokinetics
DEA is well absorbed in mice following dermal exposures, cor-
responding to approximately 27e58% of an administered dose
(Matthews et al., 1997). In this study, single doses of 8e81 mg/kg
were applied to the backs of B6C3F1 mice within 48 h. The percent
of DEA absorbed exhibited clear dose-dependency, with the lowest
percentage (27%) corresponding to the lowest tested dose (8 mg/
kg) and the highest percentage (58%) corresponding to the highest
tested dose (81 mg/kg) (Fig. 3). Dermal absorption is considerably
lower (approximately 3e16%) but also clearly dose dependent for
dermal absorption of DEA in F344 rats similarly exposed to
2.1e27.5 mg/kg (Matthews et al., 1997). Following exposure DEA is
distributed to all tissues in rodents. In tracer studies, the highest
concentrations of radiolabeled DEA are detected in the liver and
kidney of rats and mice, with tissue:blood ratios exceeding a factor
of 100 (Matthews et al., 1997). In rat liver and brain, the majority of
the radiolabel present in tissue is in the form of the parent chemical
(Matthews et al., 1995). Given that DEA is a small, water-soluble
molecule, the accumulation of DEA in liver and kidney tissues is
not likely to be driven by tissue partitioning. Studies in rats have
shown that in the liver, DEA is metabolized to a limited extent via
two general pathways (Fig. 1). DEA undergoes enzymatic methyl-
ation reactions (via transfer from S-adenosylmethionine or SAM) to
form methyl- and dimethyl-DEA, which in turn can undergo
enzymatic oxidation to form dimethylglycine-EA (Matthews et al.,
1995, 1997). In addition, DEA and its methylated metabolites can
be phosphorylated and subsequently incorporated into phospho-
lipids. The extent to which DEA is incorporated into phospholipidsis limited, and as noted above, the majority of the radiolabel
detected in liver and kidney tissue was in the form of parent
chemical (Matthews et al., 1995, 1997). Limited data collected using
human liver tissue slices indicate that these metabolic pathways
(DEA methylation, phospholipid incorporation) also occur in hu-
man tissues (Matthews et al., 1995). In rats, DEA is excreted pri-
marily in the urine as parent chemical, however a minor ringed
metabolite (N,N-dimethyl-2-oxomorpholinum) has also been
detected in urine (Matthews et al., 1997).3.1.2. Choline homeostasis
Because the proposed MOA for DEA involves perturbation of
choline homeostasis (see text below), it is important to provide
some background information on choline. Choline is an essential
nutrient used in the synthesis of phospholipids (phosphatidyl-
choline, phosphatidylethanolamine and sphingomyelin; produced
in all tissues), betaine (predominantly in liver and kidney), and
acetylcholine (predominantly in nerve tissue) (Zeisel, 2012;
Hollenbeck, 2012). Choline can be supplied by the diet, meta-
bolism of ethanolamine, or recycled from phospholipids. As a
cation, choline is absorbed from the intestinal lumen and taken up
by tissues via the organic cation transporter. Choline can be formed
by themethylation of ethanolamine (using SAM as amethyl donor),
which in turn can be oxidized to form betaine. Ethanolamine and
choline can be phosphorylated, and further metabolized for
incorporation into phospholipids (Fig. 2). Betaine can serve as
methyl donor to homocysteine, ultimately contributing to the for-
mation of SAM, which is important for methylation reactions in the
cell. The liver has a higher demand than other tissues for choline
since it synthesizes phospholipids that are secreted to plasma and
intestinal lumen. The kidney also has a higher demand for choline
since betaine serves as an important osmolyte (Obeid, 2013).
Deﬁcient levels of choline in the diet are associated with a
number of changes and adverse effects. Mice fed choline deﬁcient
diets exhibit signiﬁcant reductions in hepatic choline, SAM, and
phospholipid intermediate (phosphocholine, glycerolphosphocho-
line, phosphatidylcholine) concentrations (Lehman-McKeeman
et al., 2002). In addition, choline deﬁcient mouse hepatocytes
exhibit hypomethylation of GC-rich regions of DNA similar to that
observed with choline deﬁciency (Bachman et al., 2006), and mice
exhibit increased hepatocyte proliferation (Mellert et al., 2004;
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there is a redistribution of choline and choline-containing mole-
cules (e.g., the liver can catabolize phosphatylcholine to recover
choline) to meet the needs of critical tissues (e.g., liver, brain): (1)
decreased hepatic phospholipid secretion to plasma and intestinal
lumen; (2) increased mobilization of phospholipids in extrahepatic
tissues and increased hepatic uptake of phospholipids from plasma
(Li et al., 2007; Park et al., 2011). In the rodent liver, choline deﬁ-
ciency produces a prolonged state of steatosis (fatty liver), cell
proliferation (Zeisel, 1996), DNA hypomethylation (Locker et al.,
1986), decreased gap junction intercellular communication (GJIC;
Kamendulis et al., 2004), ﬁbrosis, necrosis, and tumors (Locker
et al., 1986; Ghoshal and Farber, 1984; Zeisel et al., 1995). Hepato-
cellular proliferation in particular is identiﬁed as an early key event,
with a 30-fold increase in DNA synthesis observed within one day
of rats placed on a methyl-deﬁcient diet (Christman et al., 1993). In
the rodent kidney, prolonged choline deﬁciency produces necrosis
and toxicity (Monserrat et al., 1969,1972;Michael et al., 1975; Zeisel
and Blusztajn, 1994). In rats, renal lesions caused by diets deﬁcient
in methionine and choline exhibited “nuclear changes in the renal
epithelium suggestive of preneoplasia …” (Newberne et al., 1968).3.1.3. Perturbation of choline homeostasis by DEA
Inspection of Figs. 1 and 2 reveal that the metabolic pathways
for DEA and for choline are very similar, and likely involve overlap
of the same enzyme systems. Thus, DEA and its metabolites serve as
structural analogs to endogenous agents important for choline
homeostasis. Speciﬁcally DEA is a structural analog of ethanol-
amine (EA), dimethyl-DEA a structural analog of choline, and
dimethylglycine a structural analog of betaine (Table 1). Because of
the high degree of overlap in metabolic pathways, there are mul-
tiple points where DEA and its metabolites can perturb choline
homeostasis (indicated by the numbered solid circles in Fig. 2).
 Inhibition of Choline Transport (points 1 and 2 in Fig. 2) e DEA
inhibits the transport of choline across cell membranes. In vitro
studies have shown that DEA inhibits uptake of choline in Syrian
hamster embryo (SHE) and Chinese hamster ovary (CHO) cells at
concentrations as low as 20 mg/L (Lehman-McKeeman and
Gamsky, 1999, 2000). Signiﬁcant decreases in hepatic choline
concentrations have been reported inmice following short-term
exposures to 80e160 mg/kg-day DEA (Stott et al., 2000;
Craciunescu et al., 2009; Lehman-McKeeman et al., 2002). Po-
tential inhibition of intestinal transport (point 1 in Fig. 2) is only
relevant to oral exposures to DEA, and Stott et al. (2000) sug-
gested that oral exposure may have occurred under the condi-
tions of the NTP mouse bioassay. Competitive inhibition of
tissue organic cation transporters would be consistent the highTable 1
Comparison of Chemical Structures of DEA and its Metabolites to Endogenous Agents.
Endogenous agents Ethanolamine C
Exogenous Analogs Diethanolamine Ddegree of DEA accumulation in mouse liver and kidney tissue
(Matthews et al., 1997; Mendrala et al., 2001).
 Decreased SAM Concentrations (point 3 in Fig. 2) e Signiﬁcant
decreases in hepatic SAM concentrations and increased S-ade-
nosylhomocysteine (SAH) concentrations have been reported in
mice following short-term exposures to 80e160mg/kg-day DEA
(Craciunescu et al., 2009; Lehman-McKeeman et al., 2002).
There are at least two ways in which DEA reduces hepatic SAM
concentrations: (1) By reducing choline and betaine concen-
trations, there is less betaine available to donate methyl groups
to homocysteine needed to regenerate SAM; and (2) SAM is
likely utilized in the metabolism of DEA to methyl- and
dimethyl-DEA (Fig. 1). Because dimethyl-DEA may not partici-
pate in methyl transfer reactions like its endogenous structural
analog, betaine, methylated metabolites of DEA may serve as
methyl sinks.
 Decreased Phospholipid Synthesis (points 4e7 in Fig. 2) e Signif-
icant decreases in hepatic phospholipid intermediates have
been reported in mice following short-term exposures to
20e160 mg/kg-day DEA (Stott et al., 2000; Craciunescu et al.,
2009; Lehman-McKeeman et al., 2002). There are at least two
ways in which DEA reduces phospholipid intermediate con-
centrations: (1) By reducing choline concentrations, there is less
available for phospholipid synthesis; and (2) In response to
lower choline levels, there may be some adaptation in mice
resulting in less phospholipid synthesis, as well as increased
phospholipid catabolism to recover choline, as part of homeo-
static mechanisms. Interestingly, the hepatic concentrations of
phospholipid sphingomyelin were increased by DEA exposure.
This result is best explained by an adaptive response of the
mouse liver to reduce the secretion of phospholipids to blood
and intestines in response to low choline levels.
 Decreased Betaine Concentrations (Point 8 in Fig. 2) - Signiﬁcant
decreases in hepatic betaine concentrations have been reported
in mice following short-term exposures to 80 mg/kg-day DEA
(Craciunescu et al., 2009). There are at least two ways in which
DEA reduces betaine concentrations: (1) By reducing choline
concentrations, there is less available for oxidation to betaine;
and (2) the oxidation of dimethyl-DEA likely occurs via the same
enzyme and requires the same co-factors (NADþ) as needed for
choline oxidation, and therefore some degree of competitive
inhibition and/or co-factor depletion is possible.
The effects of DEA on choline homeostasis are reversible upon
cessation of exposure in vivo (Lehman-McKeeman et al., 2002;
Mellert et al., 2004), and are ameliorated by choline supplemen-
tation in vitro (Lehman-McKeeman and Gamsky, 1999, 2000;
Kamendulis et al., 2004). These results indicate that the weight of
evidence is high for the essentiality of this key event in theholine Betaine
imethyl-Diethanolamine Dimethylglycine-EA
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donors cause depletion of SAM in liver, leading to DNA hypo-
methylation (Wainfan et al., 1992). These events in turn may
plausibly cause altered gene expression, creating a proliferative
stimulus that selectively promotes spontaneously mutated cells,
resulting ﬁrst in preneoplasia and eventually, if the proliferative
stimulus continues, development of tumors. In studies of B6C3F1
mice, the same strain that NTP used where dermal exposure was
reported to cause liver tumors, Newberne et al. (1982) reported
choline deﬁcient diet studies indicated “the liver of the B6C3F1
mouse is initiated by time of weaning”, and that a choline deﬁcient-
diet acts as a tumor promotor.
Based upon the information presented above, the following
events are proposed for the MOA by which DEA produces liver
tumors in mice under conditions of the NTP cancer bioassays: (1)
Exposure to DEA, primarily via the dermal route, but contributions
from the oral route (by grooming behavior following topical
application leading to oral ingestion) are also possible (Stott et al.,
2000); (2) Absorption of DEA through the skin; (3) Transport of
DEA from plasma to liver tissue; (4) Perturbation of choline ho-
meostasis, decreased SAM concentrations; (5) altered DNA
methylation; (6) Altered gene expression, cell proliferation,
apoptosis, GJIC, and cell transformation; (7) Tumor formation/
progression. The weight of evidence supporting these events, as
well as potential species differences and sources of nonlinearity are
summarized in Table 2. This information will be used to guide de-
cisions made in the dose-response assessment (Section 3.2).
Less information is available regarding the potential MOA for
DEA-induced kidney tumors in mice. Similar to responses observed
in mouse liver, sustained increases in kidney weight and DNA
synthesis were observed in male mice exposed to 160 mg/kg-day
DEA for 1e13 weeks (Mellert and Bahnemann, 2001). Increased
DNA synthesis was localized in the proximal tubules and the outer
stripe of the outer medulla, which corresponds to the location of
tumor formation. There are some additional parallels that can be
made between mouse liver and kidney tissue that support a com-
mon mode of action for both tissues. The liver and kidney reﬂect
the two tissues in mice with the highest internal exposure to DEA
(Matthews et al., 1997), likely mediated by organic cation trans-
porters. The oxidation of choline to betaine predominates in rodent
liver and kidney tissue, and betaine is normally more abundant in
these two tissues compared to other tissues (Kempson et al., 2013).
For this reason, these two tissues may be more susceptible to
perturbations of the choline/betaine/SAM pathway than other tis-
sues. As noted above, it is plausible that mouse kidney toxicity
induced by DEA could be mediated by choline deﬁciency, as lesions
akin to preneoplasia were seen in rat kidneys following treatment
with diets deﬁcient in methionine and choline (Newberne et al.,
1968). However, information currently available regarding the po-
tential role of choline perturbation in mouse kidney tumor for-
mation is insufﬁcient to make any conclusions with a reasonable
degree of conﬁdence.
3.1.4. Potential vehicle effects: interaction with ethanol
Ethanol was used as the vehicle for administering DEA and DEA
condensates in the NTP bioassays (NTP, 1999abc, 2001). Dermal
absorption of ethanol under conditions of the NTP bioassay is fairly
low (3e5%), which corresponds to absorbed ethanol doses of
approximately 40e62 mg/kg-day (Leibold and van Ravenzwaay,
2003). Ethanol has been reported to enhance the dermal perme-
ation of some agents (Heard and Screen, 2008), however this has
not been speciﬁcally evaluated for DEA. Ethanol has been found to
disrupt choline metabolism in perfused rat liver studies and in
in vitro studies using rat liver mitochondria (Barak et al., 1973;
Thompson and Reitz 1979). Dermal exposure of mice to ethanolalone, under the same conditions as the vehicle used in the NTP
cancer bioassays, resulted in a signiﬁcant decrease in hepatic
betaine concentrations (Lehman-McKeeman et al., 2002). Both
ethanol and choline oxidation share a common co-factor (NADþ).
Ethanol, through its metabolism by alcohol dehydrogenase, can
produce a signiﬁcant change in the redox status of the liver, thereby
increasing the ratio of NADH:NADþ (Barak et al., 1973; Peters and
Preedy, 1998). For this reason, one possible explanation for the
interaction of ethanol on DEA carcinogenesis is via decreasing the
concentration of the cofactor (NADþ) required for betaine syn-
thesis, and subsequently decreasing hepatic SAM levels. This po-
tential interaction is depicted by the hollow circles in Fig. 2. In
addition, ethanol has been shown to promote altered cell foci and
tumor formation in livers of experimental animals treated with
nitrosamines (Driver and McLean 1986; Takada et al., 1986), and is
widely regarded as a risk factor for cancer, including liver cancer
(IARC 1988; Seitz and Stickel 2007). Together, these data indicate
that the vehicle (ethanol) used by NTP in the cancer bioassays can
exacerbate the perturbation of choline homeostasis, which in turn
may contribute to the carcinogenic response observed in mice.
3.2. Dose-response assessment
Dose-response assessments for DEA-induced mouse liver and
kidney tumors are summarized below. Information regarding the
mode of action (Section 3.1) was used to guide key decisions made
in the dose-response assessments.
3.2.1. Endpoint/data set selection
NTP has conducted a series of cancer bioassays for DEA and
DEA-containing condensates in F344 rats and B6C3F1 mice (NTP,
1999abc; 2001). The incidence of liver tumors was increased in a
dose-dependent manner in mice of both sexes, while that for kid-
ney tumors was increased in male mice exposed to high doses
(Table 3). The incidence of liver and kidney tumors was not
increased in similarly exposed rats. The doses used in the DEA
cancer bioassay resulted in a liver tumor response (hepatocellular
adenomas, hepatocellular carcinomas, hepatoblastomas) close to
100% in all treated mice (NTP, 1999a). These data by themselves are
of limited use for characterizing a POD value (i.e., a 10% response
falls well outside the range of observation deﬁned by the data).
However, lower tumor incidence values were reported in bioassays
using test condensates with lower free DEA content levels (NTP,
1999c, 2001), and tumors were not increased in the condensate
with the lowest free DEA content (NTP, 1999b). Based upon the best
available science, the datasets from all four cancer bioassays
(Table 3) can be combined in a manner consistent with USEPA
guidelines (USEPA, 2012), which state, “Datasets that are statistically
and biologically compatible may be combined prior to dose-response
modeling, resulting in increased conﬁdence, both statistical and bio-
logical, in the calculated BMD. The simplest approach to combining
datasets is to treat the data as if they were all collected simulta-
neously.” In support of combining data sets, NTP conducted its own
logistic regression analysis of the liver tumor data from all four
cancer bioassays, and concluded that liver tumor response is pri-
marily determined by the free DEA content of each condensate
(NTP, 2001). Furthermore, visual inspection of the pooled data in
Table 3 for liver tumors and kidney tumors (renal tubule adenomas
and carcinomas) indicate that they deﬁne a consistent dose-
response relationship. Based upon these considerations, two
pooled data sets were used to characterize the cancer potency of
DEA: (1) liver tumors (adenomas/carcinomas/blastomas) in male
and female mice combined; and (2) kidney tumors in male mice.
In general, survival in treated animals was similar to control
animals with one exception. A small (~4% at the highest dose) but
Table 2
Key events in the proposed mode of Action for DEA-Induced mouse liver tumors.
Event Supporting evidence Potentially inconsistent
evidence
Potential implications to RIsk assessment Sources of nonlinearity
Animals Humans Vehicle interactions
(ethanol)
Species differences
1) Exposure Mice and rats were
dermally exposed to up
to 160 mg/kg DEA (NTP,
1999abc, 2001)
Humans are dermally
exposed to DEA in
consumer products
(Craciunescu et al.,
2009)
No data were located No data were located DEA exposures to mice
(up to 160 mg/kg-day;
NTP, 1999abc, 2001) are
orders of magnitude
higher than expected in
humans from consumer
products (Craciunescu
et al., 2009). Because of
grooming behavior,
dermal exposures to
mice may have also
included a signiﬁcant
oral component (Stott
et al., 2000)
No data were located
2) Absorption By the dermal route,
DEA is well absorbed in
mice (~27e58%), and
moderately absorbed in
rats (~3e16%)
(Matthews et al., 1997)
Dermal absorption of
DEA through human
skin is low (<1%) (Brain
et al., 2005; Kraeling
et al., 2004)
No data were located Ethanol has been
reported to enhance the
dermal permeation of
some chemicals (Heard
and Screen, 2008)
Clear species differences
are observed, with
absorption in
mice>rats>humans
(Matthews et al., 1997;
Brain et al., 2005;
Kraeling et al., 2004)
The fraction of DEA that
is dermally absorbed is
dose dependent (i.e., a
large fraction is
absorbed at higher
doses; Fig. 3)
(Matthews et al., 1997).
Repeated dermal
exposures to DEA alters
the histopathology of
mouse and rat skin
(hyperkeratosis) in a
dose-dependent
manner (NTP, 1999a).
However the impact on
of hyperkeratosis on
dermal absorption of
DEA is not known.
3) Transport from
plasma to liver
DEA preferentially
accumulates in mouse
and rat liver (Matthews
et al., 1995, 1997;
Mendrala et al., 2001).
DEA is taken up by
human liver slices
exposed to 1 mM
in vitro (Matthews
et al., 1995)
No data were located No data were located Dramatic species
differences in
hepatocyte DNA
synthesis have been
observed in vitro
(mouse~rat>>human)
(Klaunig and
Kamendulis, 2005).
These differences may
be due in part to
differential uptake (not
speciﬁcally evaluated).
Species differences in
organic cation
transporter afﬁnities
have been reported
(Dresser et al., 2000),
but have not been
evaluated speciﬁcally
for DEA.
Accumulation in liver
tissue is likely driven by
membrane transport
systems (organic cation
transporter) rather than
partitioning/passive
diffusion, and appears
to be saturable
(Matthews et al., 1995,
1997) in rodents.
Because DEA is
structurally similar to a
choline precursor
(ethanolamine), its
uptake in to liver may
be increased in a dose-
dependent manner as
choline deﬁciency
becomes manifest
4) Perturbation of
choline
homeostasis,
decreased
SAM
concentrations
Primary effect on
choline:
- Inhibiting choline
uptake into cells
in vitro at
concentrations as low
as 20 mg/L (Lehman-
McKeeman et al.,
1999, 2000)
- Decreased hepatic
choline, betaine, SAM
levels in mice exposed
to 40e160 mg/kg DEA
(Stott et al., 2000;
Craciunescu et al.,
2009; Lehman-
McKeeman et al.,
2002)
Methylation of DEA,
presumably via SAM,
reported by human
liver slices (Matthews
et al., 1995) and in
human plasma
(Craciunescu et al.,
2009)
Small discrepancy in
dose-response
concordance for SAM
reduction (Lehman-
McKeeman et al., 2002)
and tumor formation
(NTP, 1999abc, 2001).
Hepatic steatosis, a
hallmark of choline
deﬁciency, was not
observed in rats or mice
under the conditions of
the NTP bioassay.
However, there are
important differences
between dietary
choline deﬁciency and
the proposed DEA MOA
(see text in Discussion)
Ethanol oxidation
requires the same
cofactor (NADþ) as
choline and DEA
oxidation. Altering
hepatic redox status
(NADþ/NADH) may
affect choline oxidation
to betaine. Dermal
exposure to ethanol
results in decreased
betaine concentrations
(Lehman-McKeeman
et al., 2002)
There are clear species
differences in the
oxidation of choline to
form betaine, which is of
major signiﬁcance in
rodents, but a minor
pathway in humans
(Lieber and Packer,
2002; Zeisel and
Blusztajn, 1994).
Humans rely more upon
tetrahydrofolate for
maintenance of SAM.
Mice appear to be more
sensitive than rats with
respect to effects on
SAM. Short-term
exposures of rats to
64 mg/kg-day DEA
No data were located
(continued on next page)
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Table 2 (continued )
Event Supporting evidence Potentially inconsistent
evidence
Potential implications to RIsk assessment Sources of nonlinearity
Animals Humans Vehicle interactions
(ethanol)
Species differences
Additional stress on
methyl pool:
- SAM utilized during
DEA metabolism
(Matthews et al.,
1995)
- As a betaine analog,
methylated DEA
metabolites may
serve as methyl sinks
(e.g., not available for
methyl transferase
activity)
failed to have an effect
on hepatic SAM, while
short-term exposures of
mice to 80e160 mg/kg-
day DEA produced a
signiﬁcant decrease in
hepatic SAM (Stott et al.,
2000; Lehman-
McKeeman and
Gamsky, 2000, 2002;
Craciunescu et al.,
2009).
5) Altered DNA
methylation
Altered DNA
methylation reported in
mouse hepatocytes
treated with 470 mg/L
DEA in vitro (Bachman
et al., 2006)
No data were located No data were located No data were located The B6C3F1 mouse is
particularly sensitive to
hypomethylation due in
part to decreased
capacity to maintain
normal methylation
status (Counts et al.,
1996).
No data were located
6) Altered gene
expression,
DNA synthesis,
apoptosis,
GJIC, cell
transformation
- Increased DNA
synthesis and liver
weights in mice
exposed to 10
e1250 mg/kg DEA
(Mellert et al., 2004)
- Sustained increased in
DNA synthesis and
organ weights in
mouse liver and
kidney following
exposure to 160 mg/
kg-day for 1e13
weeks (Mellert and
Bahnemann, 2001)
- Altered gene
expression in mouse
hepatocytes exposed
to 500 mg/L DEA
in vitro (Kamendulis
and Klaunig, 2005)
- Increased apoptosis in
mouse neural cells
following exposure to
80 mg/kg-day
(Craciunescu et al.,
2009)
- GJIC was reduced in
mouse hepatocytes
exposed to up to
500 mg/L DEA
(Kamendulis et al.,
2004)
- DEA exposure
produced
concentration
dependent
transformations in
CHO cells in vitro
(signiﬁcant at 500mg/
L), which was
ameliorated by
choline
supplementation
(Lehman-McKeeman
and Gamsky, 2000)
DNA synthesis and GJIC
were not affected by
DEA in human
hepatocytes exposed to
up to 750 mg/L in vitro
(Kamendulis et al.,
2004; Kamendulis and
Klaunig, 2005)
No data were located No data were located Clear species differences
(mouse~rat>>human)
reported for DNA
synthesis and decreased
GJIC in hepatocytes
exposed to DEA
(Kamendulis et al.,
2004; Kamendulis and
Klaunig, 2005). Human
hepatocytes were found
to be nonresponsive for
both endpoints when
exposed to DEA.
No data were located
7) Tumor
Formation/
Progression
Clear evidence of liver
tumors in male and
female mice exposed to
40e160 mg/kg-day DEA
(NTP, 1999a) and DEA
No data were located Liver tumors not
observed in DEA
exposed rats (NTP,
1999, 2001), despite
being sensitive to
choline deﬁciency.
No data were located The background rate of
liver tumors is much
higher in mice (~60
e70%) than rats (~0e2%)
(NTP, 1999abc, 2001). In
humans, the lifetime
No data were located
C.R. Kirman et al. / Regulatory Toxicology and Pharmacology 76 (2016) 137e151144
Table 2 (continued )
Event Supporting evidence Potentially inconsistent
evidence
Potential implications to RIsk assessment Sources of nonlinearity
Animals Humans Vehicle interactions
(ethanol)
Species differences
condensates (NTP,
1999b, 2001)
Importancy
toxicokinetic
differences (absorption)
and toxicodynamic
differences (sensitivity
to hypomethylation)
may explain this
apparent inconsistency
risk of developing
cancer of the liver and
bile duct is low (0.9%)
(SEER, 2015).
Table 3
Dose-response data for tumors in mice dermally exposed to DEA-Containing mixtures (NTP, 1999abc, 2001).
Chemical (reference) Free DEA
Contentb
Daily dose (mg/kg-day)a Liver tumors (male and female mice
combined)d
Kidney tumors (male
mice)e
Test agent
administered
DEA
administered
DEA
absorbedc
DEA (NTP, 1999a) 100% 0 0 0 72/100 3/50
40 40 16.3 97/100 7/50
80 80 46.2 100/100 8/50
160 160 147 99/100 9/50
Coconut oil acid DEA condensate
(NTP, 2001)
18.2% 0 0 0 62/100 1/50
100 18.2 5.7 85/100 1/50
200 36.4 14.3 97/100 9/50
Lauric acid DEA condensate (NTP,
1999b)
0.83% 0 0 0 58/100f 0/50
100 0.83 0.20 74/99f 1/50
200 1.7 0.40 73/100 1/50
Oleic acid DEA condensate (NTP,
1999c)
0.19% 0 0 0 62/99f 0/49
15 0.029 0.0067 71/100f 0/50
39 0.074 0.018 70/100f 0/50
Bolded values indicate that the incidence was signiﬁcantly increased in male and/or female mice.
a Daily dose applied dermally 5 days/week.
b Based on reported free DEA content (NTP, 1999abc, 2001).
c Estimated based on linear regression of absorption rates as a function of dose (Fig. 3), collected by Matthews et al. (1997).
d Liver tumors include hepatocellular adenomas, carcinomas, and hepatoblastomas.
e Kidney tumors include renal tubule adenomas and carcinomas.
f The combined incidence of liver tumors was estimated by summing the incidence values for hepatocellular adenomas, carcinomas, and hepatoblastomas.
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treated with the DEA compared to controls (NTP, 1999a). However,
the survival of control animals in this study (720 days) appears to
be slightly higher than reported for control female mice (684e704
days) in the other bioassays, as well as slightly higher that reported
in control male mice (693e704 days) in the NTP bioassays (NTP,
1999abc, 2001). Because the effects of DEA treatment on survival
were not signiﬁcant or were small, incidence values for liver and
kidney tumors in treated mice were not adjusted for survival.3.2.2. Dose measure selection
In their derivation of dermal potency estimates for DEA, USEPA
relied upon allometric scaling of dose. Allometric scaling of dose to
body weight raised to the ¾ power serves as the recommended
approach by USEPA for extrapolating doses across species following
oral exposures to chemicals (USEPA, 2011). Based upon default
body weights of 0.03 and 70 kg for mice and human, respectively,
allometric scaling of dose to the ¾ power predicts that for a given
administered oral dose, humans would achieve an internal equiv-
alent dose that is approximately 7-fold higher than achieved in
mice. Allometric scaling of oral dose primarily accounts for tox-
icokinetic processes, but may also include a toxicodynamic
component. A brief discussion of toxicokinetic and toxicodynamic
factors pertinent to dermal exposures to DEA is provided below.
 Toxicokinetic Factors - With respect to toxicokinetics, the factors
that dictate chemical absorption by the oral route areconsiderably different from those for the dermal route of
exposure. For example, the thickness of stratum corneum
(humans>rats>mice; Monteiro-Riviere et al., 1990; ICRP, 2002),
which serves as the primary barrier for dermal absorption,
would suggest that for a given applied dermal dose, the internal
equivalent dose achieved in humans would be lower than that
achieved in rodents. This ﬁnding is consistent with relative rates
across species for dermal absorption of DEA in vitro (mice>r-
ats>humans; Sun et al., 1996) and in vivo (mice>rats (see Fig. 3;
Matthews et al., 1997). Sun et al. (1996) determined skin
permeability coefﬁcients for undiluted DEA and aqueous solu-
tions of DEA using skin from mice, rat, rabbits, and humans
based upon cumulative penetration of DEA over 6 h. In addition,
factors dictating the delivery and clearance of DEA to the target
tissues are not dictated by blood ﬂow and partitioning, but are
instead driven by cell membrane transport systems (organic
cation transporters, see MOA discussion), whichmay not behave
in a manner consistent with allometric scaling predictions.
 Toxicodynamic Factors e The relative sensitivity of hepatocytes
to the effects of DEA has been studied in mice, rats and humans
(Kamendulis and Klaunig, 2005). In this study, in vitro exposure
of mouse and rat hepatocytes to DEA concentrations as low as
10 mg/mL resulted in a signiﬁcant increase in DNA synthesis, in a
manner that is consistent with choline depletion. Conversely, no
increase in DNA synthesis was observed in human hepatocytes
at concentrations as high as 750 mg/mL. Treatment of the human
hepatocytes with epidermal growth factor (EGF) resulted in a 2-
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were responsive to growth stimuli. The results from this study
indicate that from a toxicodynamic standpoint human hepato-
cytes are at least 75-fold (i.e., >750/10, based on relative LOAEL
values) less sensitive than rodents to the effects of DEA. Similar
results were reported mouse, rat, and human hepatocytes with
respect to DEA effects on GJIC (Kamendulis et al., 2004).
For these reasons, allometric scaling of dose (using BW0.75) was
not used in this assessment to extrapolate dermal doses across
species. Instead, toxicokinetic differences between species were
accounted for by assessing DEA cancer potency in terms of the
dermally absorbed dose of DEA. Dermally absorbed doses for each
treatment group from the cancer bioassays were estimated in two
steps:
(1) The administered dermal DEA dose (column 4 of Table 3) was
calculated as the product of administered dose (column 3 of
Table 3) by the free DEA content (column 2 of Table 3); and
(2) The administered dermal DEA doses were converted to
absorbed doses by multiplying them by a dermal absorption
fraction. Dermal absorption fractions for DEAwere estimated
using the data of Matthews et al. (1997), who assessed the
dermal absorption of DEA in F344 rats and B6C3F1 mice
across a range of acute DEA doses. A dose-dependent in-
crease in absorption was reported in both species, with ab-
sorption being greater in mice than in rats (Fig. 3). The
relationship between the percent absorbed and dose
administered was assumed to be linear, which provided a
good ﬁt to the mouse data (R2 ¼ 0.999). To assess the ab-
sorption of DEA in the NTP cancer bioassays, this linear
relationship was extrapolated to doses both below and above
those evaluated by Matthews et al. (1997). The fraction of
DEA absorbed in mice predicted by this linear relationship
ranges from approximately 0.24 at low doses to >0.90 at the
highest doses evaluated by NTP (i.e., 160 mg/kg).
Using these two steps, the dermal absorbed doses for DEA were
estimated to range from 0.0069 to 147mg/kg-day (Table 3). For this
assessment, a highly health protective assumption was used,
namely that mice and humans are equally sensitive to DEA on an
absorbed dose basis (i.e., ignoring a potentially 75-fold difference
per the in vitro data of Kamendulis and Klaunig, 2005).3.2.3. Dose-response modeling
The dose corresponding to a 10% increase in extra risk (ED10)
and its 95% lower conﬁdence limit (LED10) were used for the POD.
POD values for DEA based upon the best ﬁtting model identiﬁed for
each data set are presented in Table 4. In terms of DEA absorbed
dose, the POD values were determined to be 0.39 and 4.3 mg/kg-
day for liver and kidney tumors, respectively (Table 4; Figs. 4 and 5).
Expressing these doses in terms of administered dose requires a
quantitative estimate of the fraction of DEA absorbed through hu-
man skin. Sun et al. (1996) reported the in vitro uptake of DEA
through human skin into receptor ﬂuid ranged from a fraction ofTable 4
Summary of POD values estimated for DEA-Induced tumors in mice.
Target tissue Sex Dose groups
Liver Males and Females combined Top 2 groups dropped
Kidney Males All
a POD values have been adjusted for discontinuous exposures (5/7 days per week) us0.0008e0.0023 (i.e., 0.08e0.23%). Although this study is considered
useful for considering the relative dermal absorption of DEA across
species (mice, rats, and humans), the study of Kraeling et al. (2004)
was used for the quantitative estimate for human skin since this
study: (1) assessed dermal absorption after 24 h of exposures, as
compared to the 6 h of exposure assessed by Sun et al., 1996); and
(2) assessed absorption from DEA-containing products to which
human populations are exposed (shampoo, hair dye, lotion), as
compared to undiluted and aqueous solutions of DEA. Kraeling et al.
(2004) measured the uptake of DEA in receptor ﬂuid after 24 h and
reported dermal absorption fractions for DEA for human skin of
0.0008 for DEA in shampoo, 0.0009 for DEA in hair dye, and 0.009
for DEA in body lotion. Based on a dermal absorption fraction of
0.009 for human skin (the maximum of the range reported by
Kraeling et al., 2004), these POD values correspond to human
equivalent doses of 43 (0.39/0.009) and 480 (4.3/0.009) mg/kg-day
for liver and kidney tumors, respectively (Table 5).3.2.4. Low-dose extrapolation
The approach for low-dose extrapolation requires a careful
consideration of the MOA by which DEA produces tumors in der-
mally exposed mice (Section 3.1, Table 2). Nonlinear and linear
approaches were evaluated. For the low-dose nonlinear approach, a
total uncertainty factor (UFt) was calculated as the product of in-
dividual components:
 UFa (interspecies variation) - A default value of 10 for interspe-
cies variation is assumed to reﬂect the product of a toxicokinetic
component (100.5 or ~3) and a toxicodynamic component (100.5
or ~3). Because the dose-response data for tumors in mice were
assessed in terms of absorbed dose, which accounts for species
differences in dermal absorption (absorption in humans is
addressed in the exposure assessment), a value of 1 is consid-
ered appropriate for the toxicokinetic component of UFa. Simi-
larly, since humans appear to be less sensitive than mice to the
effects of DEA on cell proliferation (Kamendulis et al., 2004,
2005), a value of 1 is considered to be conservative for the
toxicodynamic component of UFa for liver tumors. In the
absence of data for species differences in kidney tumor forma-
tion, a value of 3 was assumed for the toxicodynamic compo-
nent of UFa. Based on these considerations, UFa values of 1
(1  1) and 3 (1  3) were adopted for DEA liver and kidney
tumors, respectively.
 UFh (intraspecies variation) e A default value of 10 was adopted
for intraspecies variation for liver and kidney tumors. Based on a
consideration of the proposed MOA for DEA (Section 3.1),
potentially sensitive subpopulations include people with low
choline intake. Chester et al. (2011) reported that based on
NHANES (2007e8) data, mean intakes of choline in adult men
(396 mg) and women (260 mg) are below acceptable intakes for
choline (550 mg for men; 425 mg for women, but are higher for
pregnancy and lactation). Variation in choline requirements
may be due in part to genetic polymorphisms (Zeisel and da
Costa, 2009). Single nucleotide polymorphisms (SNPs) in folate
metabolizing enzymes, which may increase reliance on cholinePOD, absorbed dose (mg/kg-day)a
Best ﬁtting Model ED10 LED10
to improve model ﬁt Gamma 0.49 0.39
Dichotomous Hill 5.1 4.3
ed in the cancer bioassays.
Fig. 4. Gamma Model Fit to pooled Dose-Response Data for Liver Tumors in Male and Female Mice (2 highest dose groups dropped).
Fig. 5. Dichotomous Hill model ﬁt to pooled dose-response data for kidney tumors in male mice.
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ported to result in increased susceptibility to dietary choline
deﬁciency (Zeisel, 2008), and therefore may also result in
increased susceptibility to the effects of DEA. Nutritional de-
mands for folate and choline are increased during pregnancy
and lactation, and therefore these states may also be associated
greater susceptibility to the effects of DEA. The default uncer-
tainty factor of 10 was assumed to be protective of these
subgroups.
 UFl (LOAEL to NOAEL extrapolation) e Although BMD methods
were used to characterize the dose-response relationship forliver and kidney tumors, which would usually negate the need
to include a UFl value greater than 1, it is recognized that based
upon the severity of the endpoint considered, a 10% increase in
the extra risk of tumors does not equate to a NOAEL value. For
this reason, a value of 10 was assumed for UFl.
 UFs (subchronic to chronic extrapolation) e Because the cancer
bioassays conducted by NTP for DEA-containing agents all
include chronic exposures to DEA, a value of 1 was adopted for
UFs.
 UFd (database deﬁciency) e Because the database for DEA tu-
mors includes four cancer bioassays, each conducted in both
Table 5
Derivation of NSRL values for DEA.
Low-dose extrapolation Mouse liver tumors Mouse kidney tumors
Linear Nonlinear Linear Nonlinear
Point of Departure (POD; mg absorbed/kg-day) LED10 ¼ 0.39 LED10 ¼ 4.3
Point of Departure (POD; mg administered/kg-day)a LED10 ¼ 43 LED10 ¼ 480
Uncertainty Factor (UF) NA 100 NA 300
Reference Dose (RfDb; mg administered/kg-day) NA 0.43 NA 1.6
Cancer Slope Factor (CSFc; risk per mg administered/kg-day) 0.0023 NA 0.00021 NA
NSRL (ug/day) 300 30,000d 3,400e 110,000
a Absorbed dose values reﬂect mg of DEA absorbed through the skin, while applied dose reﬂect mg of DEA applied to the skin assuming a conservative value of 0.9%
absorption (see text). All RfD, CPF, and NSRL values are rounded to two signiﬁcant ﬁgures.
b RfD ¼ POD/UF.
c CSF ¼ 0.1/POD.
d NSRL value selected for liver tumors based upon sufﬁcient conﬁdence in the proposed mode of action.
e NSRL value selected for kidney tumors based upon insufﬁcient conﬁdence in the proposed mode of action.
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1 was adopted for UFd.
Accordingly, total uncertainty factors of 100 and 300 were
derived for liver and kidney tumors, respectively. Based on a POD
value of 43 mg/kg-day, along with a net uncertainty factor of 100, a
cancer RfD value of 0.43 mg/kg-day was derived for DEA based on
mouse liver tumors. Similarly, based on a POD value of 480 mg/kg-
day, alongwith a net uncertainty factor of 300, a cancer RfD value of
1.6 mg/kg-day was derived for DEA based onmouse kidney tumors.
For the low-dose linear approach, based on a POD value of
43mg/kg-day and a BMR of 10%, a linear estimate of cancer potency
was estimated to be 0.0023 per mg/kg-day based on DEA-induced
mouse liver tumors (Table 5). Similarly, based on a POD value of
480 mg/kg-day and a BMR of 10%, a linear estimate of cancer po-
tency was estimated to be 0.00021 per mg/kg-day based on DEA-
induced mouse kidney tumors (Table 5).
3.2.5. NSRL calculations
Based upon the available information, theweight of evidence for
DEA-induced liver tumors are sufﬁcient to support a nonlinear
approach for low-dose extrapolation, resulting in an NSRL of 30,000
ug/day (Table 5). An NSRL calculated assuming low-dose linearity
(300 ug/day) is provided for the purposes of comparison. Although
DEA-induced mouse kidney tumors likely involve a similar MOA,
signiﬁcant data gaps are noted in the weight of evidence. For this
reason an assumption of low-dose linearity was used to derive a
NSRL value of 3400 ug/day based on kidney tumors. Given that
there is a biological plausible basis for assuming mouse kidney
tumors could be caused by the threshold phenomena of DEA-
included choline deﬁciency, an NSRL based on nonlinear low-
dose extrapolation for kidney tumors (110,000 ug/day) is pro-
vided for the purposes of comparison. The NSRL value of 3400 ug/
day for DEA is considered to be protective of both liver and kidney
tumors.
4. Discussion and conclusions
Information regarding the MOA for DEA-induced mouse liver
and kidney tumors were used to support dose-response assess-
ments that resulted in derivation of NSRL values of 30,000 and
3400 ug/day, respectively. The decisions and results of dose-
response assessment conducted here are compared to those for
assessments conducted previously (USEPA, 2001, 2002;Wang et al.,
2014). For mouse liver tumors, USEPA's linear extrapolation
assumption, which essentially equates to a determination that DEA
acts via a mutagenic mode of action, yielded cancer slope factors
ranging from 0.1 to 0.4 (mg/kg-day)1. In this analysis, by usingscientiﬁc data on toxicokinetics, and still assuming a no-threshold
MOA for kidney tumors (which is likely not the case) linear
extrapolation produced a cancer slope factor of 0.0023 (mg/kg-
day)1 (Table 6)da value that is approximately 50e200 fold lower
than those resulting from USEPA's evaluation 15 years ago. Wang
et al. (2014) derived cancer slope factors ranging from 0.081 to
0.13 (mg/kg-day)-1, which are approximately 40e60 fold higher
than the value derived here (Table 6). These large differences in
potency, which translate into differences in NSRLs reﬂect differ-
ences in the decisions made at each step of the assessment
(Table 6), and highlights the importance of using knowledge of
toxicokinetics and MOA data to help guide these decisions. Since
there is moderate certainty, or even greater (depending upon the
analysis), that mouse liver tumors arise as a result of choline ho-
meostasis perturbation, a threshold MOA, the RfD value based on
this MOA of 0.43 mg/kg-day derived here is considered to more
closely represent a health protective guidance value reﬂecting the
biological pathway perturbation threshold associatedwith true risk
to humans. Consistent with the deﬁnition of an RfD (http://www.
epa.gov/risk_assessment/glossary.htm#r), exposure to DEA at
0.43 mg/kg-day would pose no appreciable risk of deleterious ef-
fects during a lifetime.
For mouse kidney tumors, previously derived cancer slope fac-
tors, based on the assumption that the DEA MOA is identical to a
mutagenic MOA, linear extrapolation calculations ranged from
0.0075 (EPA 1999, 2001) to 0.015 (Wang et al., 2014). The current
analysis, although also using linear extrapolation, took into account
knowledge of species differences in dermal absorption of DEA
(0.009 in humans vs 0.24e0.9 in mice), and thus derived a
considerably lower cancer slope factor of 0.00021 (mg/kg-day)1;
i.e., a potency that is approximately 40e80 fold lower than previous
assessments (Table 7).
Despite the fact that the cancer potency and NSRL values
derived here for DEA are orders of magnitude higher than derived
by USEPA (2001, 2002) and Wang et al. (2014), these values remain
protective of human health due to a number of health protective
assumptions made in the dose-response assessment. Sources of
conservatism in this assessment include the following: (1) The
potential impact of dermal effects of DEA at the site of application
(hyperkeratosis, hyperplasia) observed in mice (NTP, 1999a) on the
dermal absorption of DEA (i.e., increase absorption due to loss of
barrier integrity) was not quantiﬁed in the NSRL; (2) The contri-
bution of the oral pathway (Stott et al., 2000) to total dose of DEA
received bymice under the conditions of the NTP bioassay were not
included in the NSRL; (3) Dropping the two highest dose groups
from the pooled data set to improve model ﬁts resulted in slightly
lower POD values for liver tumors; (4) The exacerbation of choline
homeostasis perturbation by ethanol (Lehman-McKeeman et al.,
Table 6
Comparison of DEA assessments based on mouse liver tumors.
This analysis Wang et al. (2014) USEPA (2001, 2002)
Data Set Liver tumor (adenomas, carcinomas,
hepatoblastoma) data pooled across sex and
across bioassays for DEA and condensates (NTP,
1999a; NTP, 2001; NTP, 1999b; NTP, 1999c).
Top two dose-groups were dropped to improve
model ﬁt.
Liver tumors (carcinomas only) in
male and female mice each sex
assessed separately (NTP, 1999a)
Liver (adenomas, carcinomas, hepatoblastomas) in
male and female mice each sex and bioassay assessed
separately (NTP, 1999a, 2001)
Dose Measure Absorbed dose Administered dose Administered dose
Dose-Response Model Best ﬁtting based on visual inspection, AIC Multistage Multistage
Interspecies Extrapolation Reliance on absorbed dose, accounting for
species & product differences in absorption
Allometric scaling of administered
dose (BW^3/4)
Allometric scaling of administered dose (BW 3^/4)
POD LED10HED ¼ 43 mg/kg-day LED10HED ¼ 0.80 (F) 1.4 (M) mg/kg-
day
NA
Low-Dose Extrapolation Nonlinear (UF ¼ 100) Linear (0.1/LED10HED) Linear (q1*)a
Lifestage adjustment No Yes No
Toxicity Value RfD ¼ 0.43 mg/kg-day SF ¼ 0.081e0.13 (mg/kg-day)1 SF ¼ 0.10e0.40 (mg/kg-day)1
NSRL 30,000 ug/day 1.4 ug/day Not calculated
a q1* ¼ linear term determined for the linearized multistage model.
Table 7
Comparison of DEA assessments based on mouse kidney tumors.
This analysis Wang et al. (2014) USEPA (2001, 2002)
Data Set Kidney tumor (adenomas, carcinomas) data in males pooled
across bioassays for DEA and condensates (NTP, 1999a; NTP,
2001; NTP, 1999b; NTP, 1999c)
Kidney tumor (adenomas,
carcinomas) data in males using
DEA bioassay (NTP, 1999a)
Kidney tumor (adenomas,
carcinomas) data in males using
cocamide DEA condensate bioassay
(NTP, 1999a)
Dose Measure Absorbed dose Administered dose Administered dose
Dose-Response Model Best ﬁtting model selected based on visual inspection, AIC Multistage Multistage
Interspecies Extrapolation Reliance on absorbed dose, accounting for species & product
differences in absorption
Allometric scaling of administered
dose (BW 3^/4)
Allometric scaling of administered
dose (BW^3/4)
POD LED10HED ¼ 480 mg/kg-day LED10HED ¼ 6.6 mg/kg-day NA
Low-Dose Extrapolation Linear (0.1/LED10HED) Linear (0.1/LED10HED) Linear (q1*)a
Lifestage adjustment No Yes No
Toxicity Value SF ¼ 0.00021 (mg/kg-day)1 SF ¼ 0.015 (mg/kg-day)1 SF ¼ 0.0075 (mg/kg-day)1
NSRL 3400 ug/day NA NA
a q1* ¼ linear term determined for the linearized multistage model.
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in tumor response observed in mice were not quantiﬁed in the
NSRL; (5) Toxicodynamic differences between mouse and human
hepatocytes exposed to DEA (at least 75-fold) for cell proliferation
and GJIC were not included in the NSRL; and (6) The maximum of
the range reported for the dermal absorption fraction of DEA
through human skin was used to calculate the NSRL (0.009;
Kraeling et al., 2004), with dermal absorption fractions that are
lower by an order of magnitude were reported for some products.
To the extent product-speciﬁc information for DEA containing
products are available, a product-speciﬁc NSRL value could be
calculated using the following equation:
NSRLPS ¼ NSRL * (0.009/ABSPS) (7)
Where NSRLPS ¼ product-speciﬁc NSRL; and ABSPS ¼ product-
speciﬁc dermal absorption fraction. In this way, product-speciﬁc
NSRL values that are higher or lower than the value derived here
(3400 ug/day) can be calculated when product-speciﬁc infor-
mation is available.
Although IARC (2012) concluded there was moderate support
for a choline perturbation MOA, they also identiﬁed a number of
limitations, including: (1) no effect on hepatic levels of SAM wasobserved in mice exposed to a tumorigenic DEA dose (40 mg/kg-
day) (Lehman-McKeeman et al., 2002); (2) the role of choline
perturbation has not been established in mouse kidney tumors; (3)
although rats are highly sensitive to choline deﬁciency, no tumors
were observed in DEA-exposed rats following lifetime exposure
(NTP, 1999). The lack of published studies on the effects of
maximum tolerated doses on liver levels of choline and choline
metabolites in rats creates a critical gap in the data on the proposed
mechanism of choline-deﬁciency in the induction of liver tumors
by this chemical; (4) a hallmark of dietary choline deﬁciency, he-
patic steatosis, was not observed in rats or mice under the condi-
tions of the NTP bioassay; and (5) Catnbmutations were reported in
liver tumors from DEA-exposed mice from the NTP bioassay
(Hayashi et al., 2003), and the mutation proﬁle for mouse liver
tumors from choline-deﬁcient mice has not been characterized.
Some of these points reﬂect clear limitations. For example, the
role of choline homeostasis in mouse kidney tumor formation has
not been demonstrated, and remains an important data gap for this
assessment. However, most of these points warrant additional
discussion. With respect to point (1), the apparent lack of dose-
response concordance between SAM and liver tumors may be
attributable to differences in exposure duration (four weeks for
SAM effects vs. two years for tumorigenic effects), such that the
effects on SAM may become more pronounced with longer dura-
tions. In addition, differences in other factors in experimental
conditions (e.g., dietary choline, folate levels) can also contribute to
C.R. Kirman et al. / Regulatory Toxicology and Pharmacology 76 (2016) 137e151150differences in their observed dose-response relationships. Lastly,
the control animals serving as the basis of comparison for statistical
signiﬁcance in Lehman-McKeeman et al. (2002) were vehicle con-
trols (exposed to ethanol), rather than untreated controls, which
may have contributed to lower SAM levels due to its effects on
hepatic betaine (i.e., SAM levels in the ethanol-exposed animals
may be lower than in naïve animals).
As to point (3), the absence of tumors in rats under the condi-
tions of the NTP cancer bioassays may be due in part to the lower
dermal absorption fraction reported for rats compared to that for
mice (Fig. 3; Matthews et al., 1997). On an absorbed dose basis, the
systemic exposures of rats to DEA were approximately 2- to 5- fold
lower than corresponding mouse exposures. Because B6C3F1 mice
are uniquely sensitive to hypomethylation stress (Counts et al.,
1996), a factor that may contribute to their very high background
rate of liver tumors, rats may require much higher doses of DEA
than do mice.
With respect to point (4), there are important differences be-
tween “systemic choline deﬁciency” produced by feeding a choline-
deﬁcient diet and the “perturbations of choline homeostasis” pro-
duced by dermal exposures to DEA. For example, hepatic choline
measures alone following DEA exposure may not reﬂect actual ef-
fects on cell signaling, since DEA and its metabolites are structural
analogs (Table 1) may contribute to endogenous signaling pro-
cesses. Craciunescu et al. (2009) reported that hepatic choline
concentrations inmicewere reduced from777 nmol/g to 232 nmol/
g following repeated exposure to 80 mg/kg-day DEA; however, the
concentration of the structural analog dimethyl-DEA in DEA treated
mice (1216 nmol/g) exceeds the control concentration of choline. In
addition, mice fed choline deﬁcient diets will develop systemic
choline deﬁciency (i.e., low tissue concentrations throughout the
body). In contrast, inhibiting choline transport from plasma to liver
by DEA results in lower concentrations of DEA in the liver; however,
choline levels in plasma may remain unchanged or may even be
elevated due to this inhibition. For this reason, systemic signals of
choline deﬁciency, which may factor in to systemic responses for
lipid mobilization in extrahepatic tissues, may not be present in
DEA-exposed mice. This is one possible explanation for why he-
patic steatosis, a hallmark of choline deﬁciency, was not observed in
mice or rats under the conditions of the NTP bioassay.
Lastly, with respect to point (5), the presence of mutations in
DEA-induced mouse liver tumors is not evidence of a direct geno-
toxic MOA. During tumor progression, mutations or some type of
genetic alteration are a necessary step for all cancers. Genetic
changes or mutations that occur during the processes of cell pro-
liferation and clonal expansion (in some cases due to genomic
instability) are not the events that deﬁne a mutagenic MOA. As
noted, non-genotoxic carcinogens such as oxazepam and pheno-
barbital, also result in increased liver tumors exhibiting Catnb
mutations without H-ras mutations, which may reﬂect selective
pressure during tumor promotion (Hayashi et al., 2003). Addi-
tionally, DNA methylation plays an important role in genomic sta-
bility, and hypomethylation can lead to genomic instability and
increased mutations rates (Chen et al., 1998).
Overall, a role for choline homeostasis perturbation in the MOA
for DEA-inducedmouse liver tumors is well supported (Leung et al.,
2005). Further research in the areas discussed above would help
reduce uncertainties associated with the cancer MOA for DEA, and
in turn would improve conﬁdence in the NSRL values derived in
this assessment. The NSRL values derived here are intended for DEA
applied dermally, and are not considered appropriate for assessing
oral exposures to DEA. The NSRL values reported here are derived in
a manner that takes into account DEA absorption through human
skin and can be modiﬁed when data or knowledge is available for
product speciﬁc absorption characteristics.Acknowledgments
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